DigiCon

DEMOGRAPHIC DATA

@if(isset(session()->get('doctor')['vCentralCode']))

Name *

@else

Name *

@endif

City of Practice *

Years of Practice *

Practicing at *

Private Hospital Government Hospital Charitable Trust Private Clinic

what percentage of your patients get incidentally diagnosed with non-alcoholic fatty liver disease (NAFLD)? *

a. < 25%

b. 25-50%

c. 50-75%

d. >75%

How you proceed with your patients incidentally diagnosed with NAFLD? *

a. Investigate for presence of metabolic alterations and the absence of other liver diseases

b. Assess the risk of metabolic alterations and liver function with non-invasive scoring system in absence of other chronic liver disease

c. Investigate presence of alcohol consumption

d. Advise lifestyle modification and regular follow up

e. Initiate pharmacotherapy

In your practice, approximately what percentage of your type 2 diabetes mellitus patients have NAFLD? *

a. <10%

b. 10 -20%

c. 20 – 50 %

d. 50 – 80%

e. >80%

Type 2 diabetes mellitus and non-alcoholic fatty liver disease usually co-exists. *

a. Strongly Agree

b. Slightly Agree

c. Neutral

d. Slightly Disagree

e. Strongly Disagree

When do you consider screening your type 2 DM patients for NAFLD? *

a. Liver disease symptoms like fatigue, loss of appetite,

b. Increased LFTs

c. Type 2 DM for > 5 years

d. Screen all type2 DM patients yearly as a routine practice

e. Others

In your type 2 DM patients with NAFLD, which of the following scoring methods do you use for the assessment of severity of NAFLD ? (You can tick multiple options) *

a. BARD score

b. Fibrometer

c. NAFLD fibrosis score

d. APRI score

e. Fib-4

f. AST/ ALT ratio

g. Others

h. none

Which of the following data/ laboratory parameters do you routinely ask in your type 2 DM patients diagnosed with NAFLD? (You can tick multiple options) *

a. Body mass index (BMI)

b. Waist circumference

c. Blood pressure measurement

d. Blood glucose levels

e. Glycosylated hemoglobin

f. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

g. Lipid profile

h. Other

Prophylactic management of fatty liver in diabetic patients reduces progression of NAFLD *

a. Strongly Agree

b. Slightly Agree

c. Neutral

d. Slightly Disagree

e. Strongly Disagree

When do you consider referring your type 2 DM patients with NAFLD to a Gastroenterologist/ Hepatologists? (You can tick multiple options) *

a. Patients with persistent elevated AST/ALT

b. Patients having intermediate/ high risk (FIB 4> 1.3, LSM>8 kpa)

c. When Fibrosis stage is 3 & above

d. MRI / CT confirmed fibrosis

e. Others

In what percentages of your NAFLD and NASH patients do you prescribe a pharmacological therapy? (Only Numeric)*

a. Percentage of NAFLD patients

b. Percentage of NASH patients

Which of the following drugs do you prescribe most commonly for management of NAFLD/ NASH? (Please tick maximum three options) *

a. Anti-oxidant vitamins

b. Hepato-protectant agents

c. Obeticholic acid

d. Saroglitazar

e. Pioglitazone

f. Others

In diabetics with NAFLD, what is the common duration you prescribe a hepatoprotective agent? *

a. One month

b. 2-3 months

c. Up to 6 months

d. Until LFTs is back within normal limits

e. Continue along with diabetic medications

Once confirmed for NAFLD, how frequently do you follow up NAFLD/ NASH patients? *

a. Once in 3 months

b. Once in 6 months

c. Once in a year

Do you consider NAFLD status while choosing anti-diabetic therapy for your diabetic patients with NAFLD? *

a. Yes

b. No

c. Depends on severity of NAFLD

Diabetes and NAFLD are strongly co-related and should be grouped together for developing management strategies *

a. Strongly Agree

b. Slightly Agree

c. Neutral

d. Slightly Disagree

e. Strongly Disagree

Anti-diabetic drugs with additional benefits on fat metabolism are sufficient to manage NAFLD *

a. Strongly Agree

b. Slightly Agree

c. Neutral

d. Slightly Disagree

e. Strongly Disagree

Do you consider NAFLD as a pandemic which needs urgent attention? *

a. Yes

b. No

c. May be

Which of the following do you consider as barrier for the management of NAFLD in your type 2 DM patients? (You can tick multiple options) *

a. Time constraint

b. Cost of evaluation and treatment

c. Lack of confidence in managing it

d. Lack of awareness in patients

e. Lack of availability of effective drugs

f. No barriers